Cato Elisabeth Andree Corsten

Cato Elisabeth Andree Corsten

Auto-generated profile, based on publicly available information

Cato Elisabeth Andree Corsten


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2022 in Cells
Verified
Journal Article
Open access
PDF file
Steven C. KoetzierSteven C. Koetzier
Steven C. Koetzier
JLJamie Van Langelaar
Jamie Van Langelaar
MMMarie-José Melief
Marie-José Melief
AWAnnet F. Wierenga-Wolf
Annet F. Wierenga-Wolf
CCCato E. A. Corsten
Cato E. A. Corsten
JSJoost Smolders
Joost Smolders
The effector programs of CD8+ memory T cells are influenced by the transcription factors RUNX3, EOMES and T-bet. How these factors define brain-homing CD8+ memory T cells in multiple sclerosis (MS) remains unknown. To address this, we analyzed blood, CSF and brain tissues from MS patients for the impact of differential RUNX3, EOMES and T-bet expression on CD8+ T cell effector phenotypes. The frequencies of RUNX3- and EOMES-, but not T-bet-expressing CD8+ memory T cells were reduced in the blood of treatment-naïve MS patients as compared to healthy controls. Such reductions were not seen in MS patients treated with natalizumab (anti-VLA-4 Ab). We found an additional loss of T-bet in RUNX3-expressing cells, which was associated with the presence of MS risk SNP rs6672420 (RUNX3). RUNX3+EOMES+T-bet− CD8+ memory T cells were enriched for the brain residency-associated markers CCR5, granzyme K, CD20 and CD69 and selectively dominated the MS CSF. In MS brain tissues, T-bet coexpression was recovered in CD20dim and CD69+ CD8+ T cells, and was accompanied by increased coproduction of granzyme K and B. These results indicate that coexpression of RUNX3 and EOMES, but not T-bet, defines CD8+ memory T cells with a pre-existing brain residency-associated phenotype such that they are prone to enter the CNS in MS.

24 July 2023 in Multiple Sclerosis Journal – Experimental, Translational and Clinical
Verified
Journal Article
Open access
ISIde Smets
Ide Smets
MVMatthijs Versteegh
Matthijs Versteegh
SHSimone Huygens
Simone Huygens
CCCato Corsten
Cato Corsten
BWBeatrijs Wokke
Beatrijs Wokke
JSJoost Smolders
Joost Smolders
Background: In high-income countries, four anti-CD20 monoclonal antibodies (mAbs) are used or in the pipeline for relapsing MS: ocrelizumab, ofatumumab (both registered), ublituximab (awaiting registration) and rituximab (off-label). List prices differ significantly between registered and off-label drugs. Objective: Comparing differences in benefits between anti-CD20 mAbs from a health-economic and societal perspective. Methods: To reflect lifetime use of DMTs, we used a treatment-sequence model to compare ocrelizumab/ofatumumab and eight other drug classes in terms of health (lifetime relapses, time to Expanded Disability Status Scale [EDSS] 6, lifetime quality-adjusted life years) and cost-effectiveness (net health benefit). To become cost-effective compared to ocrelizumab, we modelled the list price of ublituximab and desired effect on EDSS progression of rituximab. Results: Although drug sequences with ocrelizumab in first- and second-line were more cost-effective than ofatumumab, our probabilistic analysis suggests this outcome was very uncertain. To be more cost-effective than ocrelizumab, ublituximab needs to be about 25% cheaper whilst rituximab needs to equal the effect on disability progression seen with first-line treatments. Conclusions: Our model showed no clear difference in cost-effectiveness between ocrelizumab and ofatumumab. Hence, prescribing the least costly anti-CD20 mAb can democratise MS care without a loss in health benefits.

22 October 2023 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Open access
CCCato E.A. Corsten
Cato E.A. Corsten
SHSimone A. Huygens
Simone A. Huygens
MVMatthijs M. Versteegh
Matthijs M. Versteegh
BWBeatrijs H.A. Wokke
Beatrijs H.A. Wokke
ISIde Smets
Ide Smets
JSJoost Smolders
Joost Smolders
Three sphingosine-1-phosphate receptor (S1PR) modulators are currently available as disease-modifying therapies (DMTs) for relapsing MS in the Netherlands (i.e. fingolimod, ozanimod and ponesimod). We aimed to identify which S1PR modulator yields the highest benefit from a health-economic and societal perspective during a patient's lifespan. Incorporating Dutch DMT list prices, we used the ErasmusMC/iMTA MS model to compare DMT sequences, including S1PR modulators and eight other DMT classes, for treatment-naïve patients with relapsing MS in terms of health outcomes (number of lifetime relapses, time to Expanded Disability Status Scale (EDSS) 6, lifetime quality-adjusted life years (QALYs)) and cost-effectiveness (net health benefit (NHB)). We estimated the influence of list price and EDSS progression on cost-effectiveness outcomes. In deterministic and probabilistic analysis, DMT sequences with ponesimod have lower lifetime costs and higher QALYs resulting in a higher average NHB compared to sequences with other S1PR modulators. Ponesimod remains the most cost-effective S1PR modulator when EDSS progression is class-averaged. Given the variable effects on disability progression, list price reductions could make fingolimod but not ozanimod more cost-effective than ponesimod. Our model favours ponesimod among the S1PR modulators for the treatment of relapsing MS. This implies that prioritizing ponesimod over other S1PR modulators translates into a more efficacious spending of national healthcare budget without reducing benefit for people with MS. Prioritizing cost-effective choices when counselling patients contributes to affordable and accessible MS care.

9 February 2026 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
CCCato E. A. Corsten
Cato E. A. Corsten
VGVeerle S. A. Geraedts
Veerle S. A. Geraedts
AMAna M. Marques
Ana M. Marques
MMMarie-José Melief
Marie-José Melief
BVBarry Koelewijn - van Vliet
Barry Koelewijn - van Vliet
JSJoost Smolders
Joost Smolders
Introduction: Serum neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) may synergistically enhance early risk stratification of multiple sclerosis (MS) diagnosis after clinically isolated syndromes (CIS). We investigated the prognostic value of combined NfL and GFAP for McDonald 2024 MS diagnosis after CIS and associations with key genetic and environmental risk factors. Methods: CIS participants, within six months after symptom onset, were included in a prospective cohort. We measured baseline serum NfL and GFAP levels and calculated z-scores. We evaluated weighted genetic risk scores for MS susceptibility, HLA-DRB1*15:01 risk and measured Anti-Epstein Barr virus Nuclear Antigen-1 (anti-EBNA1) immunoglobulin G (IgG) antibodies. Associations with MS diagnosis were evaluated using Cox proportional hazards models and time-dependent receiver operating characteristic (ROC) analyses. Results: During follow-up, 162/221 CIS participants were diagnosed with McDonald 2024 MS. Separately, high NfL and GFAP associated with earlier MS diagnoses (hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.12–1.66, p = 0.002, HR 1.12, 95% CI 1.02–1.42, p = 0.01, respectively). In combined models, only NfL remained independently predictive (HR 1.30, 95% CI 1.02–1.60, p = 0.01). Time-dependent ROC analyses showed similar results for NfL alone and combined with GFAP. HLA-DRB1*15:01-risk, but not GFAP or anti-EBNA1 IgG, improved predictive value. Conclusion: Our study found that serum NfL outperformed GFAP in predicting early MS diagnoses after CIS. Baseline NfL, together with HLA-DRB1*15:01 status, provides robust early risk stratification for MS after CIS, whereas GFAP and anti-EBNA1 titres add limited prognostic value. Additional immunological and imaging markers are essential to further refine predictive models.

16 July 2024 in Brain
Verified
Journal Article
Closed access
PDF file
CCCato E A Corsten
Cato E A Corsten
BWBeatrijs H A Wokke
Beatrijs H A Wokke
JSJoost Smolders
Joost Smolders
Cato E A Corsten, Beatrijs H A Wokke, Joost Smolders; Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size, Bra

5 January 2026 in Annals of Neurology
Verified
Journal Article
Open access
CCCato E. A. Corsten
Cato E. A. Corsten
AMAna M. Marques
Ana M. Marques
EVElisabeth J. Vinke
Elisabeth J. Vinke
CMC. Louk de Mol
C. Louk de Mol
RNRinze F. Neuteboom
Rinze F. Neuteboom
JSJoost Smolders
Joost Smolders
The risk allele rs10191329*A is associated with disease severity and brain atrophy in people with multiple sclerosis (MS). We investigated the association of rs10191329 with age‐related brain atrophy in a population‐based cohort using 10,308 magnetic resonance imaging (MRI) scans of 4,815 participants aged ≥ 45 years without MS in cross‐sectional and longitudinal analyses. We observed associations between the rs10191329*A allele and lower total brain volume and gray matter volume in middle‐aged (< 55 years of age), but not in older participants. These data suggest that rs10191329*A contributes to earlier onset of atrophy in the general population, and that mediating mechanisms of accelerated neurodegeneration extend beyond MS. ANN NEUROL 2026;99:1083–1089